Tri K. Nguyen

发表

The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation

Paul Dent, P. Dent, S. Grant, 2007, Molecular Pharmacology.

The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress

P. Dent, S. Grant, M. Rahmani, 2007, Molecular and Cellular Biology.

Enhancing Covid-19 virus spread modeling using an activity travel model

Nam H. Hoang, Tri K. Nguyen, G. Currie, 2022, Transportation Research Part A: Policy and Practice.

Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.

P. Dent, S. Grant, Yun Dai, 2007, Blood.

Cancer Therapy : Preclinical HDAC Inhibitors Potentiate the Activity of the BCR / ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or-Resistant BCR / ABL þ Leukemia Cells In Vitro and In Vivo

S. Grant, M. Muschen, Yun Dai, 2011 .

Abstract 2686: The CDK inhibitor dinaciclib (SCH727965) inhibits the unfolded protein response (UPR) through a CDK1- and CDK5-dependent mechanism

S. Grant, Tri K. Nguyen, 2014 .

Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism

S. Grant, Tri K. Nguyen, 2013, Molecular Cancer Therapeutics.

Abl/Src inhibitor BMS-354/825 MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual

P. Dent, S. Grant, H. Harada, 2013 .

MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.

P. Dent, S. Grant, H. Harada, 2007, Blood.

Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate

B. Druker, P. Dent, S. Grant, 2006, Clinical Cancer Research.

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

J. Friedberg, R. Fisher, P. Dent, 2010, Leukemia research.

Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.

P. Dent, S. Grant, Tri K. Nguyen, 2006, Leukemia research.

Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.

G. Kellogg, S. Grant, S. T. Eblen, 2009, Bioorganic & medicinal chemistry letters.

Activation of eukaryotic initiation factor-2α-kinases in okadaic acid-treated neurons

S. M. Kim, Tri K. Nguyen, S. Yoon, 2010, Neuroscience.

The kinase inhibitor sorafenib induces cell death through a process involving induction of ER stress

P. Dent, S. Grant, M. Rahmani, 2007 .

THE MULTIKINASE INHIBITOR SORAFENIB INDUCES APOPTOSIS IN HIGHLY IMATINIB MESYLATE-RESISTANT BCR/ABL + HUMAN LEUKEMIA CELLS IN ASSOCIATION WITH STAT5 INHIBITION AND MCL-1 DOWN-REGULATION

P. Dent, S. Grant, M. Rahmani, 2007 .

Activation of eukaryotic initiation factor-2α-kinases in okadaic acid-treated neurons

Tri K. Nguyen, S. Yoon, S. Kim, 2010, Neuroscience.

Abstract 2572: The histone deacetylase inhibitors (HDACIs) vorinostat and entinostat interact synergistically with the Bcr/Abl, FLT3, and aurora kinase inhibitor KW-2449 to induce apoptosis in imatininb mesylate (IM)-sensitive and -resistant CML and ALL cellsin vitroandin vivo

S. Grant, Yun Dai, Lora B. Kramer, 2011 .

Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism

S. Grant, Tri K. Nguyen, 2013, Molecular Cancer Therapeutics.